Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.83)
# 663
Out of 4,876 analysts
486
Total ratings
43.39%
Success rate
10.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $14.78 | +103.05% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.63 | +1,804.76% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.80 | +1,002.94% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $13.30 | +351.30% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.65 | +105.48% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.05 | +326.23% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.33 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.46 | +1,206.62% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $7.21 | +870.87% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.61 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $17.21 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.43 | +2,690.70% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.25 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.87 | +306.61% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $49.45 | -29.22% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $56.20 | +33.45% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $9.86 | +112.98% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $51.07 | +40.98% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $300.28 | +34.87% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $3.69 | +49.05% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $36.52 | +160.13% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $7.50 | +140.00% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.69 | +252.30% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.13 | +59.74% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $18.57 | +158.48% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $3.82 | +96.34% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.00 | +397.56% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $8.64 | +50.46% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.71 | +33,588.94% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.22 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $22.65 | +10.38% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.81 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.60 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $26.52 | -73.60% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.93 | -29.84% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.44 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $14.78
Upside: +103.05%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.63
Upside: +1,804.76%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.80
Upside: +1,002.94%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $13.30
Upside: +351.30%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.65
Upside: +105.48%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.05
Upside: +326.23%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.33
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.46
Upside: +1,206.62%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $7.21
Upside: +870.87%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.61
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $17.21
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.43
Upside: +2,690.70%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $7.87
Upside: +306.61%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $49.45
Upside: -29.22%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $56.20
Upside: +33.45%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $9.86
Upside: +112.98%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $51.07
Upside: +40.98%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $300.28
Upside: +34.87%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $3.69
Upside: +49.05%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $36.52
Upside: +160.13%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $7.50
Upside: +140.00%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.69
Upside: +252.30%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.13
Upside: +59.74%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $18.57
Upside: +158.48%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $3.82
Upside: +96.34%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.00
Upside: +397.56%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $8.64
Upside: +50.46%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.71
Upside: +33,588.94%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $22.65
Upside: +10.38%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.81
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.60
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $26.52
Upside: -73.60%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.93
Upside: -29.84%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.44
Upside: -